Precigen is expected to report Q3 2026 consensus revenue of $71.56 million and earnings per share of $0.09, while the stock currently trades at $5.42, well below the average analyst price target of $13.67.
The primary focus for investors is the commercial sales momentum of Papzimeos, the company's gene therapy for recurrent respiratory papillomatosis, particularly following the recent FDA approval of a direct competitor from Inovio Pharmaceuticals.
Precigen's stock recently experienced significant volatility after Inovio's rival therapy received an accelerated nod, intensifying pressure on management to prove its market dominance and pricing power.
Analysts are also looking for updates on the company’s cash runway and its stated goal of reaching cash flow breakeven by the end of 2026 as Papzimeos commercialization scales.